Verastem (VSTM), a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer.
VSTM programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.
VSTM's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.
VSTM's duvelisib is in Phase 3 randomized and two-arm trial for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with refractory indolent non-Hodgkin lymphoma.
VSTM has license agreement with Infinity Pharmaceuticals, Inc.; The Scripps Research Institute; and Pfizer (PFE).
Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts.
- October 9, 2015 - 9:24am | Research Notes
- September 28, 2015 - 8:48am | Research Notes
- August 26, 2015 - 4:39pm | Research Notes
- August 26, 2015 - 10:27am | Research Notes
- July 26, 2015 - 11:46am | Research Notes
- July 18, 2015 - 3:33pm | Research Notes
- July 12, 2015 - 5:53pm | Research Notes
- July 5, 2015 - 3:07pm | Research Notes
- June 10, 2015 - 7:18am | BOD & C-Suite Updates
- January 22, 2015 - 8:58pm | Financings
- January 21, 2015 - 10:03am | Financings
- January 20, 2015 - 10:06am | Research Notes
- January 16, 2015 - 9:00am | Research Notes
- January 8, 2015 - 8:47am | BOD & C-Suite Updates
- December 29, 2014 - 11:28am | BOD & C-Suite Updates
- December 26, 2014 - 9:01am | BOD & C-Suite Updates
- December 18, 2014 - 9:36am | BOD & C-Suite Updates
- December 11, 2014 - 9:16am | Research Notes
- November 21, 2014 - 12:41pm | Research Notes
- November 14, 2014 - 1:58pm | Earnings